Strongbridge Biopharma - Stock Price History | SBBP

Historical daily share price chart and data for Strongbridge Biopharma since 2021 adjusted for splits. The latest closing stock price for Strongbridge Biopharma as of September 27, 2021 is 2.14.
  • The all-time high Strongbridge Biopharma stock closing price was 10.05 on October 16, 2015.
  • The Strongbridge Biopharma 52-week high stock price is 4.26, which is 99.1% above the current share price.
  • The Strongbridge Biopharma 52-week low stock price is 1.85, which is 13.6% below the current share price.
  • The average Strongbridge Biopharma stock price for the last 52 weeks is 2.60.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Strongbridge Biopharma Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.8454 2.0000 4.4000 1.5700 2.4300 16.27%
2019 3.2790 4.4400 5.5900 1.4700 2.0900 -53.35%
2018 6.1945 7.5500 8.8500 3.8700 4.4800 -38.21%
2017 5.2169 2.3500 7.9500 2.2000 7.2500 202.08%
2016 4.4571 7.0900 7.0900 2.3000 2.4000 -68.42%
2015 7.1853 10.0500 10.0500 5.6500 7.6000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.145B $0.031B
Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing's syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29